<DOC>
	<DOCNO>NCT00276159</DOCNO>
	<brief_summary>The purpose study evaluate anti-tumor activity 852A use treat certain hematologic malignancy respond standard treatment .</brief_summary>
	<brief_title>Study Immune Response Modifier Treatment Hematologic Malignancies</brief_title>
	<detailed_description>852A administer subcutaneous injection ( SC ) 2 time per week 12 week ( 24 dos ) provision dose escalation reduction base tolerability</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<criteria>Subjects eligible study meet follow Diagnosis one follow hematologic malignancy respond least 2 standard treatment regimen . Any criteria persistent recurrent disease acceptable , i.e . ≥5 % blast acute leukemia . acute lymphoblastic leukemia ( ALL ) acute myeloid leukemia ( AML ) nonHodgkin 's lymphoma ( NHL ) Hodgkin 's lymphoma ( HL ) multiple myeloma ( MM ) chronic lymphocytic leukemia ( CLL ) Performance status Karnofsky &gt; 50 % patient &gt; 10 year age Lansky &gt; 50 % patient &lt; 10 year age Normal organ function within 14 day study entry If female childbearing potential , willing use adequate contraception ( hormonal , barrier method , abstinence ) prior study entry duration study participation . A female consider childbearing potential unless uterus remove , double oophorectomy , amenorrheic least 6 month chemotherapy Had/have follow prior/concurrent therapy : Systemic corticosteroid ( oral injectable ) within 7 day first dose 852A ( topical inhale steroid allow ) Investigational drugs/agents within 14 day first dose 852A Immunosuppressive therapy , include cytotoxic agent within 14 day first dose 852A ( nitrosoureas within 30 day first dose ) Drugs know induce QT interval prolongation and/or induce Torsades De Pointes unless best available drug require treat lifethreatening condition Radiotherapy within 4 week first dose 852A Hematopoietic cell transplantation 4 week first dose 852A Active infection fever &gt; 38.5°C within 3 day first dose 852A Cardiac ischemia , cardiac arrhythmia congestive heart failure uncontrolled medication History , clinical evidence , condition , opinion investigator , could confound result study put subject undue risk Uncontrolled intercurrent chronic illness Active autoimmune disease require immunosuppressive therapy within 30 day Active hepatitis B C evidence ongoing viral replication Hyperthyroidism Uncontrolled seizure disorder Active coagulation disorder control medication Pregnant lactating Concurrent malignancy ( remission , least 5 year disease free ) except localize ( insitu ) disease , basal carcinomas cutaneous squamous cell carcinoma adequately treat Proven active central nervous system ( CNS ) disease Human Immunodeficiency Virus ( HIV ) positive Congenital long QT syndrome abnormal baseline QTc interval ( &gt; 450 msec male &gt; 470 msec female ) Bazett 's correction ( QTc msec = QT msec / square root RR interval second ) screen electrocardiogram ( ECG ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Myeloma</keyword>
	<keyword>Hematology</keyword>
	<keyword>852A</keyword>
	<keyword>IRM</keyword>
	<keyword>Oncology</keyword>
</DOC>